Blue Sky Elearn
Blue Sky Elearn is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study).
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
Operational learnings available6 trial-level findings · Read insights
- Of 336 screened patients, 102 initially failed screening; 15 were rescreened and 13 subsequently became eligible.
- Protocol Version 5.0 excluded confirmed COVID-19 from the major-infection definition for the primary endpoint and clarified the effect of altered COVID-19 hospital-admission criteria on major-infection reporting.
- Protocol Version 6.0 permitted repeat IgG testing during screening and rescreening for any patient who failed screening.
- Protocol Version 6.0 removed the scheduled additional safety-panel laboratory visit 7–10 days after the first investigational-product infusion.
- Protocol Version 7.0 added sites in Türkiye, Greece, Spain, and the Czech Republic, removed Israel, and increased the planned site count from approximately 50 to 70.
- No global trial interruptions or restarts were reported.
These findings describe the trial, not the service provider’s performance or responsibility.
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded-Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Blue Sky Elearn?
The 2026-10-09 snapshot links Blue Sky Elearn to 6 distinct CTIS trials. Recorded services include Training Services, Investigator Meeting Planner, Provide web based training portal for the study, training vendor, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Blue Sky Elearn?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Blue Sky Elearn conducted?
The linked trials record locations in 20 countries, including Germany, Italy, Spain, Greece, Belgium. These are trial locations, not confirmed office locations or countries where Blue Sky Elearn delivered services.
What can this page tell me about Blue Sky Elearn's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Blue Sky Elearn. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Blue Sky Elearn LLC